Advanced search
Publication Cover
Hematology Volume 28, 2023 - Issue 1
Submit an article Journal homepage
2,433
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Abatacept as salvage therapy for life-threatening refractory autoimmune hemolytic anemia: a case report

Joerg Hoffmanna Department of Hematology, Oncology and Immunology, Philipps University Marburg, University Hospital Giessen and Marburg, Marburg, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2820-1501View further author information
ORCID Icon,
Georg Schliesserb Practice for Hematology and Oncology Giessen, Giessen, GermanyView further author information
&
Andreas Neubauera Department of Hematology, Oncology and Immunology, Philipps University Marburg, University Hospital Giessen and Marburg, Marburg, GermanyView further author information
Article: 2208010 | Received 22 Feb 2023, Accepted 24 Apr 2023, Published online: 03 May 2023

References

  • Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013;163:393–399.
  • Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol. 2017;92:23–27.
  • Kotb R, Pinganaud C, Trichet C, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005;75:60–64.
  • Moyo VM, Smith D, Brodsky I, et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood. 2002;100:704–706.
  • Hantaweepant C, Pairattanakorn P, Karaketklang K, et al. Efficacy and safety of second-line treatment in Thai patients with primary warm-type autoimmune hemolytic anemia. Hematology. 2019;24:720–726.
  • Walker LSK, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11:852–863.
  • Hess J, Su L, Nizzi F, et al. Successful treatment of severe refractory autoimmune hemolytic anemia after hematopoietic stem cell transplant with abatacept. Transfusion. 2018;58:2122–2127.
  • Genovese MC, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med. 2005;353:1114–1123.
  • Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907–1915.
  • Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;4:1206–1212.
  • Wing K, Onishi Y, Prieto-Martin P. CTLA-4 control over Foxp3+ regulatory T cell function. Science [Internet]. 2008 [cited 2022 Feb 6]; Available from: https://www.science.org/doi/abs/10.1126science.1160062.
  • Mqadmi A, Zheng X, Yazdanbakhsh K. CD4 + CD25 + regulatory t cells control induction of autoimmune hemolytic anemia. Blood. 2005;105:3746–3748.
  • Richards AL, Kapp LM, Wang X, et al. Regulatory T cells are dispensable for tolerance to RBC antigens. Front Immunol. 2016;7:348.
  • Ward FJ, Hall AM, Cairns LS, et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood. 2008;111:680–687.
  • Ahmad E, Elgohary T, Ibrahim H. Naturally occurring regulatory T cells and interleukins 10 and 12 in the pathogenesis of idiopathic warm autoimmune hemolytic anemia. J Investig Allergol Clin Immunol. 2011;21:8.
  • Pavkovic M, Georgievski B, Cevreska L, et al. CTLA-4 exon 1 polymorphism in patients with autoimmune blood disorders. Am J Hematol. 2003;72:147–149.
  • Schubert D, Bode C, Kenefeck R, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20:1410–1416.
  • Dhunputh C, Ducassou S, Fernandes H, et al. Abatacept is useful in autoimmune cytopenia with immunopathologic manifestations caused by CTLA-4 defects. Blood. 2022;139:300–304.
  • Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol. 2019;102:157–162.
  • Galindo-Navarro P, Delgado-García A, Rodríguez-Gil MA. Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain. Haematologica [Internet]. 2020 [cited 2023 Apr 10]; Available from: https://haematologica.org/article/view/haematol.2022.281850.
  • Karlsson C, Hansson L, Celsing F, et al. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia. 2007;21:511–514.
  • Nader K, Patel M, Ferber A. Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2013;13:511–513.
  • Montillo M, O’Brien S, Tedeschi A, et al. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood Cancer J. 2017;7:e524.
  • Kuter DJ, Rogers KA, Boxer MA, et al. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: phase 2, multicenter, open-label study. Am J Hematol. 2022;97:691–699.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.